Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 3, Pages 667
Publisher
MDPI AG
Online
2023-01-23
DOI
10.3390/cancers15030667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity
- (2022) Yonglin Chen et al. Frontiers in Immunology
- The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy
- (2022) Hiroyuki Takahashi et al. Cells
- The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia
- (2021) Panagiotis Giamougiannis et al. CARCINOGENESIS
- The Role of Tumor Inflammatory Microenvironment in Lung Cancer
- (2021) Zhaofeng Tan et al. Frontiers in Pharmacology
- CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels
- (2021) Yi-Sheng Wang et al. Annals of Translational Medicine
- A Potential Role of IL-6/IL-6R in the Development and Management of Colon Cancer
- (2021) Mimmo Turano et al. Membranes
- Molecular Biology Networks and Key Gene Regulators for Inflammatory Biomarkers Shared by Breast Cancer Development: Multi-Omics Systems Analysis
- (2021) Su Yon Jung et al. Biomolecules
- Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer
- (2020) Nirmala Chandralega Kampan et al. Scientific Reports
- Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
- (2020) Aleksandra Gentry-Maharaj et al. Cancers
- Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
- (2019) Vincent Dochez et al. Journal of Ovarian Research
- The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
- (2018) Ali Masjedi et al. BIOMEDICINE & PHARMACOTHERAPY
- Diagnostic value of HE4 in ovarian cancer: A meta-analysis
- (2018) Jinbing Huang et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis
- (2018) Landon Browning et al. Cancer Management and Research
- The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer
- (2018) Juan Zhou et al. Frontiers in Oncology
- Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients
- (2017) Rodrigo da Silva et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- TNFR2: A Novel Target for Cancer Immunotherapy
- (2017) Éva S. Vanamee et al. TRENDS IN MOLECULAR MEDICINE
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells
- (2017) Nirmala Chandralega Kampan et al. Frontiers in Immunology
- Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities
- (2017) Nirmala Chandralega Kampan et al. CURRENT MEDICINAL CHEMISTRY
- Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer
- (2016) Soochi Kim et al. CANCER SCIENCE
- A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
- (2015) E. M. Dijkgraaf et al. ANNALS OF ONCOLOGY
- Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers
- (2015) Denis Lane et al. BMC CANCER
- Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
- (2015) Fan Yan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Plasma immune analytes in patients with epithelial ovarian cancer
- (2015) Matthew S. Block et al. CYTOKINE
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
- (2015) Silvia Darb-Esfahani et al. Oncotarget
- Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
- (2015) Nirmala Chandralega Kampan et al. Biomed Research International
- Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
- (2014) Chindu Govindaraj et al. AMERICAN JOURNAL OF HEMATOLOGY
- HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review
- (2014) N. S. Karlsen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
- (2013) Patrizia Pinciroli et al. BMC GENOMICS
- Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment
- (2013) Chindu Govindaraj et al. CLINICAL IMMUNOLOGY
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum
- (2013) Jaime Prat et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- TNFR2 Is Critical for the Stabilization of the CD4+Foxp3+ Regulatory T Cell Phenotype in the Inflammatory Environment
- (2013) X. Chen et al. JOURNAL OF IMMUNOLOGY
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- 1H–13C NMR-based urine metabolic profiling in autism spectrum disorders
- (2013) Sylvie Mavel et al. TALANTA
- Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2
- (2013) Yoshiaki Okubo et al. Scientific Reports
- Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research
- (2013) Nuzhat Ahmed et al. Frontiers in Oncology
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
- (2012) Eveline M. Dijkgraaf et al. CURRENT PHARMACEUTICAL DESIGN
- Inflammation and ovarian cancer
- (2012) Antonio Macciò et al. CYTOKINE
- Interleukin-6 - A Key Regulator of Colorectal Cancer Development
- (2012) Maximilian J. Waldner et al. International Journal of Biological Sciences
- Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2
- (2012) Sharon Cohen et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
- (2011) T Van Gorp et al. BRITISH JOURNAL OF CANCER
- Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells
- (2011) K. E. Hamilton et al. MOLECULAR CANCER RESEARCH
- Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells
- (2010) Yue Wang et al. CANCER LETTERS
- Phase II biomarker trial of a multimarker diagnostic for ovarian cancer
- (2010) Tracey Edgell et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3- Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells
- (2010) X. Chen et al. JOURNAL OF IMMUNOLOGY
- HE4: a new potential early biomarker for the recurrence of ovarian cancer
- (2010) Emanuela Anastasi et al. TUMOR BIOLOGY
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
- (2008) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
- Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery
- (2008) Tomoki Ito et al. IMMUNITY
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
- (2007) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
- Distinguishing benign and malignant pelvic masses: The value of different diagnostic methods in everyday clinical practice
- (2006) Mirjam J.A. Engelen et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started